Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Current Quarter	$-0.16	Next Quarter	$-0.12
Current Year	$-0.79	Next Year	$-0.39
QoQ Growth	+25.0%	YoY Growth	+50.6%
3Y EPS CAGR	-43.9%	Target Price	$3.00
Consensus	Buy	Upside	+756.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CODX	$0.35	+8.66%	959.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CODX	$0.35	+8.7%	959.86K
3
4
5
6

CODX

CODX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Co-Diagnostics Inc. Data in Excel

Get Co-Diagnostics Inc. Data in Excel